Abstract: The present invention provides novel hybridoma cell lines which produce monoclonal antibodies (MoAbs) that bind epitopes found on lipopolysaccharide most commonly associated with the endotoxin core of gram negative bacteria and exhibit broad cross-reactivity with gram negative bacteria of different genera and effectively neutralize endotoxin. At least one of the MoAbs disclosed (XMMEN-J5D) binds an epitope also found on gram positive bacteria. The hybridomas are produced by fusing an immortal cell, a cell having the ability to replicate indefinitely in myeloma cell culture, and an effector immune cell following immunization of the immune cell host with a preparation of a gram negative bacteria. While several individual hybridoma cell lines producing monoclonal antibodies to lipopolysaccharide are described, the present invention adds to the state of the art an entire family of hybridoma producing monoclonal antibodies to lipopolysaccharide-associated epitopes.

Abstract: The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor.

Abstract: Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma.Hydridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively.

Abstract: The invention relates to a method of screening for fibrin clot-specific monoclonal antibodies and to the monoclonal antibodies screened by this method. The invention also relates to immundiagnostic and immunotherapeutic applications of the screened fibrin clot-specific monoclonal antibodies.

Abstract: A protein having a molecular weight of from about 10,000 to 18,000 daltons, isoelectric points of from about pH 4.0 to 6.5 and having the reversible biological effect of inhibiting aromatase activity in a biological system, and antibodies to the protein, modulate follicular development and spermatogenesis and provide for diagnostic tests of gonadal functions.

Abstract: Monoclonal antibodies to angiotensin II and the continuous hybrid monoclonal cell lines for their production are provided. These antibodies are useful in the diagnosis and treatment of angiotensin II-induced hypertension.

Abstract: A method of determining CK-MB isoenzyme in a biological fluid is disclosed which comprises subjecting a sample of said fluid to an assay system which includes incubating with monoclonal antibody specific to CK-MB isoenzyme, but not reactive with CK-MM or CK-BB. Methods for preparing antibodies with these characteristics and cell lines producing them are also disclosed.

Abstract: The invention describes a new process for the production of anti-viral diagnostics, as well as an example of one antibody useful in detecting a wide variety of pathogenically important alphaviruses. The process includes, but is not limited to, the isolation of monoclonal antibodies directed against internal viral components. Such antibodies may be generated by conventional immunization in vivo or in vitro using subviral particles or synthetic peptides corresponding to specific viral proteins. Alternatively, synthetic peptides derived from the cytoplasmic domains of envelope proteins may be used to elicit monoclonal idiotypic and anti-idiotypic antibodies following immunization in vitro and/or in vivo.The anti-alphavirus antibody included in the invention is an example of the type of reagent produced. It was produced as an anti-idiotype against monoclonal antibodies to a synthetic peptide derived from Semliki Forest virus.

Abstract: A method is disclosed for detecting the presence of HTLV III infected cells in a medium. The method comprises contacting the medium with monoclonal antibodies against an antigen produced as a result of the infection and detecting the binding of the antibodies to the antigen. The antigen may be a gene product of the HTLV III virus or may be bound to such gene product. On the other hand the antigen may not be a viral gene product but may be produced as a result of the infection and may further be bound to a lymphocyte. The medium may be a human body fluid or a culture medium. A particular embodiment of the present method involves a method for determining the presence of a AIDS virus in a person. The method comprises combining a sample of a body fluid from the person with a monoclonal antibody that binds to an antigen produced as a result of the infection and detecting the binding of the monoclonal antibody to the antigen. The presence of the binding indicates the presence of a AIDS virus infection.

Abstract: Monoclonal antibodies reactive with oncogenic and activated ras p21 proteins containing glutamic acid, arginine or valine at position 12 and unreactive with normal ras p21 proteins containing glycine at position 12. The antibodies are secreted by hybridomas obtained by immunizing mice with synthetic dodecapeptides corresponding in amino acid sequence to positions 5-16 of normal ras p21 proteins, except having glutamic acid, arginine or valine in place of glycine at position 12. The antibodies and Fab fragments thereof are useful for diagnosis, staging and classification of malignant and premalignant lesions.

Abstract: High-yielding hybridoma cell lines which secrete monoclonal antibodies capable of binding to tumor cells of one or more types, but not normal cells can be obtained more readily by fusing myeloma cells with antibody-forming cells isolated from an animal immunized with tumor antigens, which has previously been made immunological tolerant to normal cell antigens, comprising the total antigens, or at least a proportion of the total antigens, of the normal cells corresponding to the tumor cells chosen as the source of immunizing antigens.

Abstract: Monoclonal antibodies being capable of reacting with human squamous cell lung carcinoma, lung adenocarcinoma and large cell lung carcinoma, and non-reactive with human small cell lung carcinoma and normal human lung cells, and recognizing glycoproteins as antigens. Hybridomas having the characteristics of cell line SLC-454 secrete such antibodies. Method of diagnosing human lung cancer and method of therapeutic treatment are described.

Abstract: A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.

Abstract: This invention relates to a method for the active or passive immunization of a vertebrate against ectoparasites and endoparasites, and a method of treating a vertebrate host infected by ectoparasites or endoparasites, comprising administering to the vertebrate an immunogen comprising one or more endocrine products of ectoparasites and endoparasites, coupled with an immunogenic carrier, or administering to the vertebrate, monoclonal antibodies capable of binding to the native form of the endocrine product.

Abstract: The present invention is concerned with novel monoclonal antibodies specific for an antigenic site on a protein characteristic of a human basal cell and a malignant squamous cell. The antibodies do not bind to mesenchymal cells such as fibroblasts and endothelial cells. The protein on the cell surface which binds to one of the antibodies has a molecular weight of about 120,000 as determined by one dimensional gel electrophoresis. The antibodies find use in diagnostic methods such as the detection of malignant cells, e.g., the detection of residual tumor cells in skin subjected to microscopically-controlled surgery.

Abstract: A method is described for the detection of halodeoxyuridines taken up by cells during DNA synthesis by the use of monoclonal antibodies. The described method also allows the simultaneous detection of cell surface receptors.

Abstract: Hybridomas which produce monoclonal antibodies specific to an abnormal branched determinant of a synthetic glycolipid antigen and methods of use of the monoclonal antibodies.

Abstract: There are provided monoclonal antibodies which react with human oncofetal ferritin and which do not react with human spleen ferritin or with liver ferritin; there are also provided monoclonal antibodies which react both with human placenta oncofetal ferritin and with human adult spleen ferritin. There is provided a process for producing clones producing such antibodies and such clones, and an assay for the detection of human breast cancer based on the determination of oncofetal ferritin, which assay is based on such monoclonal antibodies.

Abstract: This invention relates to novel proteins useful for enhancing pulmonary surfactant activity, methods for obtaining said proteins and compositions containing one or more of the proteins. The proteins of this invention include the following:1. A protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 1.2. A protein characterized by a molecular weight of about 35 kd and by being encoded for by the DNA sequence depicted in Table 2.3. A protein encoded for by a portion of the DNA sequence depicted in Table 6 and characterized by a molecular weight of about 5.5-9 kd; and4. A protein characterized by a molecular weight of about 5.5-9 kd and an amino acid composition as set forth in Table 4.

Abstract: The present invention is concerned with two novel monoclonal antibodies which define carbohydrate antigens associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in the lung of a subject. The method involves examining tissue from the subject for the presence of antigens which are Le.sup.x or Le.sup.y antigen or which have the characteristics of Le.sup.y and Le.sup.x.

Abstract: Analogs of hGH having the activity of naturally occurring hGH and a similar amino acid sequence varying from the sequence of natural hGh by the addition of one or more amino acids, e.g. methione or methionine-leucine, to the N-terminus of natural hGH have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to increase the level of hGH in the subject.Analogs of hGH which comprise the amino acid sequence of natural hGH from the N-terminus of which one or more amino acids have been deleted, e.g. Met.sup.14 hGh, have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to lower the level of hGH in the subject.A plasmid has been constructed which directs the expression of an analog of hGH having the amino acid sequence methionine-leucine added to the N-terminus of natural hGH.

Abstract: T. Cruzi polypeptide antigens that react with serum from chagasic individuals and does not cross-react with serum from uninfected individuals or individuals infected with related parasites such as Leishmania is described. The DNA from T. Cruzi culture trypomastigotes and epimastigotes coding for antigenic material having a molecular weight of 70 kd is identified, sequenced, and inserted into a cloning vector, which, in turn, is inserted into a host cell line. The expressed polypeptide is immunologically reactive with sera from Chagas' disease infect patients. The cloned gene for the 70 kd polypeptide is expressed and purified and a diagnostic test for Chagas' disease comprising the synthesized polypeptide is described.

Abstract: An analysis of LEU3, a leucine-specific regulatory locus encoding a factor for control of RNA levels of a group of leucine-specific genes, is provided.DNA sequence analysis of a clone of LEU3 shows that it contains an open reading frame of 886 amino acids. There are three regions of particular interest: a cluster of acidic amino acids that are located in the C-terminal half of the coding region, a region with a repeated cysteine motif, and a region of partial homology with MATalpha2. A LEU3-dependent DNA binding activity is demonstrated to interact with homologous portions of the 5'-region of LEU1 and LEU2.

Abstract: Monoclonal antibodies specific for an antigen present on the surface of parathyroid tissue are useful in imaging such tissue when conjugated to suitable label. The antibodies of the invention bind exclusively to parathyroid surfaces and do not bind to other tissues. The antibodies are useful in establishing the location of the parathyroid whether in its normal location or in ectopic placements. An exemplary monoclonal has been deposited at the American Type Culture Collection and has accession number ATCC No. HB9917.

Abstract: The present invention provides a lymphocyte-mediated immunotherapy for the treatment of human or animal subjects afflicted with abnormal or tumor cells which express a MHC Class II antigen on their surface. The method utilizes inducer T-cell clones or lines having a demonstrable specificity for an identifiable antigen. These T-cells are activated in-vivo to express cytolytic and therapeutic activity against the abnormal or tumor cells in the subject.

Abstract: Hybrid receptors are provided that comprise (a) the ligand binding domain of a predetermined receptor and (b) a heterologous reporter polypeptide. The hybrid receptors are useful for convenient and large scale assay of biologically active ligands or their antagonists or agonists.

Abstract: Monoclonal antibodies specifically immunologically reactive to thiol-modified glutathione and hybridoma cell lines producing such monoclonal antibodies. A method of producing antibodies specifically immunologically reactive with reduced glutathione by immunizing an animal using a thiol-modified glutathione, for example, a glutathione-N-ethylmaleimide-keyhole limpet hemocyanin conjugate. A method of utilizing the antibodies produced to quantitate the amount of reduced glutathione in a biological sample, to monitor glutathione-associated conditions, to monitor the formation of normal metabolic intermediates and to monitor the detoxification of foreign compounds.

Abstract: This invention relates to the production of antibodies to angiogenin or to fragments thereof and to methods of inhibiting angiogenesis in mammals by administering to mammals such antibodies or Fab fragments thereof so as to inhibit angiogenic activity. In addition, this invention relates to pharmaceutical compositions comprising therapeutically effective amounts of antibody that are immunologically reactive with angiogenin and which can be administered to inhibit angiogenesis.

Abstract: Method and compositions including monoclonal antibodies to a serogroup-common antigen are provided for the detection and diagnosis of Legionella pneumophila. The monoclonal antibodies recognize a proteinaceous antigen of molecular weight 28,000-29,000 Daltons which is detected in at least serogroups 1 through 8 of Legionella pneumophila and is not detected in other common respiratory pathogens.

Abstract: A new cell line has been made which is capable of producing an antibody that reacts with melanoma associated tumors cells. Antigens capable of reacting with the new antibody have been isolated and characterized. Methods are disclosed for the utilizing the antibody and antigen of the present invention and diagnostic procedures for determining the identity and extent of melanoma associated disease. The compositions of the present invention are disclosed to be useful in other immunological procedures.

Abstract: A method and composition for killing target cells is disclosed. The method utilizes ex vivo IL-2 activation of leucocyte effector cells and arming the activated leucocyte effectors with monoclonal antibodies whose Fc portions bind to the IL-2-activated effectors and whose paratopic portions immunoreact with an epitope expressed on the surfaces of the target cells. The composition contains a cytolytic amount of the armed, IL-2-activated effector cells dispersed in an aqueous physiologically tolerable diluent medium.

Abstract: A monoclonal antibody which specifically binds to the human IL-2 receptor, and a hybridoma which produces the antibody, are disclosed.

Abstract: Monoclonal antibodies, and hybridoma cell lines for their production, that bind with a high degree of specificity proteins associated with HTLV-III virus are presently disclosed. In particular, transmembrane envelope glycoprotein gp41 (41,000 dalton molecular size), major core antigen p24 (24,000 dalton molecular size), and p17 protein (17,000 dalton molecular size) are disclosed. The proteins to which the present monoclonal antibodies respond are essentially antigenically distinct from HTLV-I and HTLV-II. SVM-16 is an IgM monoclonal antibody, SVM-23 is an IgG.sub.2 monoclonal antibody, and SVM-26 is an IgG.sub.1 monoclonal antibody, all of which bind to p24. SVM-25 is an IgG.sub.1 monoclonal antibody binding gp41, and SVM-33 is an IgG.sub.1 monoclonal antibody binding p17. All the monoclonal antibodies of the present invention are produced in hybridoma cells prepared by fusing myeloma cells with spleen cells from mammals, such as mice, immunized with lysates of purified virus.

Abstract: A secondary monoclonal antibody against a complex of a molecule of molecular weight less than 5000 and a binding protein against said molecule which secondary monoclonal antibody is not an antibody against molecule or against its binding protein.

Abstract: A monoclonal antibody preparation having a single binding activity, which activity is in respect of a cell surface antigen, comprises IgG antibody molecules in which only one of the two light chains will bind to said antigen, the proportion of such antibody molecules being enhanced relative to IgG antibody molecules having two light chains which will bind to said antigen to thereby produce an enhancement of the binding activity of the preparation. Such preparations containing predominatly "monovalent antibodies" are of particular value in the areas of transplantation immunity, the treatment of neoplastic disease and cell sorting.

Abstract: There is disclosed a process for rendering a labile protein-containing composition, substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said composition with an effective amount of a fatty acid or a soluble ester, alcohol or a salt thereof for a sufficient period of time to inactivate virus contained therein.

Abstract: Monoclonal antibodies reactive with epiglycanin.

Abstract: The invention provides a method for selecting hybridomas which produce antibodies specific to domains of a cell surface antigen which is usually not accessible at the surface of intact cells. The method employs the screening of the hybridoma clones obtained for the production of antibodies specific against the cell surface antigen by use of immunoblotting analysis, namely by screening the clones against antigen immobilized on a solid substrate such as nitrocellulose. The invention also includes those hybridomas and monoclonal antibodies when produced according to the method. The method provides monoclonal antibodies to P-glycoprotein surface antigen correlated with multidrug resistance. The antibodies are used to obtain a cDNA probe which in turn was used to select a cDNA clone encoding for a portion of the P-glycoprotein including the C-terminal end.

Abstract: Novel monoclonal antibodies to an aflatoxin B.sub.1 and G.sub.1 in a test kit and used in a method of testing are described. The method for producing the monoclonal antibodies uses repeated administration of aflatoxin B.sub.1 or the related analog compound as a 1-position polypeptide to a murine and production of a hybridoma to generate the novel monoclonal antibodies. The novel antibodies have limited cross-reactivity to aflatoxins B.sub.2, G.sub.2 and M.sub.1. Aflatoxin B.sub.1 or aflatoxin G.sub.1 are detected in foods and the like using the test kit and method.

Abstract: A hybrid cell line yields a monoclonal antibody which is highly restricted to B-lineage lymphoblastic leukemia cells and their progenitors.

Abstract: Radioimmunotoxins consisting of a monoclonal antibody covalently coupled to a toxin and a radionuclide. The compositions retain high binding specificity and cytotoxic activity and are useful in treating cancer and in bone marrow transplantation. The antibody component determines the selectivity. The toxin component kills the targeted cells. The radionuclide component also kills, but by a different mechanism, thus ensuring the eradication of all tumor cells. The radionuclide also allows the radioimmunotoxin to be tracked in vivo which enables the determination of its distribution throughout the body. Also, the pharmacokinetics of injected radioimmunotoxin can be determined allowing for more exact dose quantitation and administration.

Abstract: Competitive immunoassays, which employ idiotypic and antiidiotypic monoclonal antibody reagents, are described. These competitive immunoassays are particularly useful for the detection of low concentrations of analyte for which labeled reference analyte is difficult to obtain in quantity. Antiidiotypic monoclonal antibody reagents serves as a substitute for the labeled reference analyte. The antiidiotypic monoclonal antibody reagent exhibits a congruency of structure with one or more epitopes of the analyte or antigen. The antiidiotypic monoclonal antibody is prepared against an idiotypic monoclonal antibody, which, in turn, was prepared against the antigen or analyte. During the immunoassay, the antiidiotypic monoclonal antibody is allowed to compete with the antigen, whose concentration is being determined, for a limited number of antibody binding sites present on an idiotypic antibody, which was also prepared against the antigen or analyte.

Abstract: A diagnostic site-specific imaging reagent in the form of a receptor and an indicating means selectively binds to a specific cell membrane-associated antigen of a blood platelet that is in a stimulated active state but does not substantially bind to a platelet that is in a non-stimulated resting state. In particular, prelabelled monoclonal antibodies and polyclonal antibodies are prepared that bind and image thrombospondin when it is cell membrane-associated on a thrombin-stimulated platelet, thereby providing means for detecting and discriminating between a stimulated active blood platelet and a non-stimulated resting blood platelet.

Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.

Abstract: A competitive immunoassay for a steroid receptor has been developed in which monoclonal antibodies capable of binding to the steroid receptor are competitively bound by anti-steroid antibodies capable of binding to the steroid. The presence or amount of monoclonal antibody-anti-steroid antibody complex formed is related to the amount of steroid receptor present in the assayed material.A histochemical assay is also provided for detecting the amount of a steroid-receptor complex in a biological sample. This assay involves (1) adding an amount of steroid to the sample to form a steroid-receptor complex; (2) contacting the complex with a monoclonal antibody capable of binding to the complex; (3) removing any unbound monoclonal antibody; (4) adding a detectably labeled antibody capable of binding to the monoclonal antibody; (5) determining the amount of labeled antibody bound to the monoclonal antibody; and (6) determining the amount of steroid-receptor complex.

Abstract: A mammalian monoclonal receptor is produced by a hybridoma formed by fusion of cells from a myeloma cell line and lymphocytes that produce antibodies that react with a viral antigen from a mammal immunized with cytomegalovirus-infected cells. The monoclonal receptor reacts with the viral antigen in a diagnostic system to detect the presence of cytomegalovirus in a biological sample.

Abstract: Hybridoma HB 8986 produces a murine monoclonal antibody which recognizes a new determinant expressed in bronchopulmonary carcinomas and A549 cell line derived tumors. Immunoperoxidase staining with the hybridoma on formalin fixed, paraffin embedded tissues shows that it specifically stains both the cytoplasmic and cell surface. The monoclonal antibody has the ability to distinguish preferably bronchopulmonary carcinomas with glandular differentiation from other bronchopulmonary carcinomas. Additionally, the monoclonal antibody may identify adenocarcinomas through the body.

Abstract: Methods are disclosed for preparing (1) a pure, biologically active, immunogenic tumor-associated antigen by forming a soluble pool of membrane proteins from antigenic tissue and, by separating, identifying and characterizing antigenic and/or immunogenic proteins therefrom; (2) an ultrapure, biologically active TAA by further subjecting the pure TAA to isotachophoresis and/or affinity chromatography; and (3) making an epitope from purified TAA by injecting TAA into a host animal to stimulate the production by lymphocytes of antibodies specific to TAA, forming hybridomas capable of secreting monoclonal antibodies reactive with the TAA, dividing the TAA into fragments including epitopes, forming epitope-monoclonal antibody complexes, separating the complexes to recover the epitopes, and thereafter identifying and characterizing the epitopes.

Abstract: Highly stable pharmaceutical compositions suitable for parenteral administration to animals or humans comprising a therapeutically effective amount of an RTA-immunoconjugate dissolved in an inert carrier method comprising a stabilizer are claimed. Screening methods for selecting stabilizers effective in preventing precipitation and aggregation of such compositions are described. Preferred stabilizers includes glycerol at a concentration (v/v) of from about 25 to about 35%; dextran sulfates having molecular weights from about 0.1.times.10.sup.6 to about 2.times.10.sup.6 daltons; and human serum albumin.The invention further comprises such compositions which have been lyophilized and/or reconstituted wherein the stabilizer is non-volatile, and may further comprise a carbohydrate stabilizer.The invention further comprises stabilized RTA compositions.

Abstract: A conjugate, which is the reductive amination product of an immunogenic capsular polymer fragment, having a reducing end and derived from the capsular polymer of a bacterial pathogen, and the non-toxic polypeptide binding subunit of the heat-labile enterotoxin of Escherichia coli (LT-BNT). Also disclosed, are methods for the preparation of the conjugates and for the preparation of vaccines containing the conjugates which elicits an effective level of antibodies in humans. By administering an immunogenic amount of the conjugates, active immunization against systematic infection in young mammals caused by bacterial pathogens can be induced.